Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders
The go-to CMC and bioprocessing podcast for process development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.
Practical, execution-focused guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics.
Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.
This podcast is for you if:
- You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership
- You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness
- You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny
- You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources
What you will learn:
CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling and manufacturing economics, continuous manufacturing and Industry 4.0 in biopharma, biologics modalities including mAbs, ADCs, and cell and gene therapies.
Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.
Next Steps:
Book a free assessment to reduce biomanufacturing costs and make lifesaving therapies more accessible: https://bruehlmann-consulting.com/assessment
Fast-track bioprocess development with expert guidance: https://bruehlmann-consulting.com
Visit the Website: https://smartbiotechscientist.com
Email us: hello@bruehlmann-consulting.com
Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders
234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 2
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.
Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.
Highlights from the episode:
- When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).
- Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).
- Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).
- Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).
- The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).
- The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).
- Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).
- Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).
Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.
Connect with Anthony Catacchio:
LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b
Product Insight website: www.productinsight.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here